|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Ovarian cancer stem cells: Can targeted therapy lead to improved progression-free survival?显示文摘Despite significant effort and research funds, epithelial ovarian cancer remains a very deadly disease. There are no effective screening methods that discover early stage disease; the majority of patients are diagnosed with advanced disease. Treatment modalities consist primarily of radical debulking surgery followed by taxane and platinum-based chemotherapy. Newer therapies including limited targeted agents and intraperitoneal delivery of chemotherapeutic drugs have improved disease-free intervals, but failed to yield longlasting cures in most patients. Chemotherapeutic resistance, particularly in the recurrent setting, plagues the disease. Targeting the pathways and mechanisms behind the development of chemoresistance in ovarian cancer could lead to significant improvement in patient outcomes. In many malignancies, including blood and other solid tumors, there is a subgroup of tumor cells, separate from the bulk population, called cancer stem cells(CSCs). These CSCs are thought to be the cause of metastasis, recurrence and resistance. However, todate, ovarian CSCs have been difficult to identify, isolate, and target. It is felt by many investigators that finding a putative ovarian CSC and a chemotherapeutic agent to target it could be the key to a cure for this deadly disease. This review will focus on recent advances in this arena and discuss some of the controversies surrounding the concept. | Christen L Walters Haygood Rebecca C Arend J Michael Straughn Donald J Buchsbaum | 2014 | World Journal of Stem Cells2014，6，4： | 7 |
| 2 | Immunohistoehemical evaluation of the c-kit proto-oncogene in sarcomas of the uterus:a case series显示文摘 | Leath CA 3rd Straughn JM Jr Conner MG | 2004 | J Reprod Med2004，49，2： | 1 |
| 3 | Effect of TRA- 8 anti-death receptor 5 antibody in combination with chemotherapy in an ex vivo human ovarian cancer mode显示文摘 | Frederick PJ Kendrick JE Straughn JM Jr | 2009 | Int J Gynecol Cancer2009，19，5： | 1 |
| 4 | Pharmacokinetics of chlorpheniramine,phenytoin,glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele显示文摘 | Kidd RS Straughn AB Meyer MC | 1999 | Pharmacogenetics1999，9，1： | 1 |
| 5 | A modern view of excipient effects on bioequivalence: case study of sorbitol 显示文摘 | CHEN ML STRAUGHN AB SADRIEH N | 2007 | PharmRes2007，24，1： | 1 |
| 6 | The Wnt/β-catenin pathway in ovarian cancer:a review显示文摘 | Arend RC Londo?o-Joshi AI Straughn JM Jr | 2013 | Gynecol Oncol2013，131，3： | 1 |
| 7 | Clinical implications of a ris- ing serum CA-125 within the normal range in patients with epithelial ovarian cancer : a preliminary investigation 显示文摘 | Wilder JL Pavlik E Straughn JM | 2003 | Gynecol Oncol2003，89，2： | 1 |
| 8 | Expression of sperm protein 17(Sp17) in ovarian cancer显示文摘 | Straughn JM Jr Shaw DR Guerrero A | 2004 | Int J Cancer2004，108，6： | 1 |
| 9 | Chemotherapy for advanced and recunenlcervical carcinoma: results from cooperative group trials显示文摘 | Leath C A Straughn J M | 2013 | Gyneco-logic oncology2013，129，1： | 1 |
| 10 | Pharmacokinetics of clorpheniramine, phenytoin, glipizide, and nefedipine in an individual homozygous for the CYP2C9 * 3 allele 显示文摘 | Kidd RS Straughn AB Meyer MC | 1999 | Pharmacogenetics1999，9，1： | 1 |
| 11 | Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian canc- er 显示文摘 | Frederick PJ Straughn JM Alvarez RD | 2009 | Gynecologic Oncology2009，113，3： | 1 |
| 12 | The effect of gelatin cross-linking on the bioequivalence of hard and soft gelatin acetaminophen capsules 显示文摘 | Marvin C M Straughn A Mhartre R M | 2000 | Pharm Res2000，17，8： | 1 |
| 13 | Immunohistochemical evaluation of the c-kit proto-oncogene in sarcomas of the uterus, a case series显示文摘 | Leath CA Straughn JM Jr Conner MG | 2004 | J Reprod Med2004，49，2： | 1 |
| 14 | Anti-tumor activity of TRA-8 anti-death receptor 5 ( DR5 ) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model显示文摘 | Straughn J M Jr P G Oliver T Zhou | 2006 | Gynecol Oncol2006，101，1： | 1 |
| 15 | Expression of sperm protein 17(Sp17) in ovarian cancer显示文摘 | Straughn J M Jr Shaw D R Guerrero A | 2004 | Int J Cancer2004，108，6： | 1 |
| 16 | Occult eho- discovered by positron emission tomography/ computed tomography imaging following a successful pregnancy 显示文摘 | Numnum TM Leath CA 3rd Straughn JM Jr | 2005 | Gynecol Oncol2005，97，2： | 1 |
| 17 | Anti-tumor activity of TRA-8 anti-death receptor 5(DR5)monoclonal antibody in combination with chemotherapy and radiat ion therapy in a cervical cancer model显示文摘 | Straughn JM Jr Oliver PG Zhou T | 2006 | Gynecol Oncol2006，101，1： | 1 |
| 18 | The role of comprehensive surgical staging in patients with endometrial cancer 显示文摘 | Frederick PJ Straughn JJ | 2009 | Cancer Control2009，16，1： | 1 |
| 19 | The role of radical parametrectony in the treatment of occult cervical carcinoma after extrafascial hysterectomy显示文摘 | Leath CA Ⅲ Straughn JM Jr BhoolaSM | 2004 | Gynecol Oncol2004，92，2： | 1 |
| 20 | Preclinical stud-ies and clinical utilization of monoclonal antibodies in epithelial o-varian cancer显示文摘 | Frederick PJ Straughn JM Jr Alvarez RD | 2009 | Gynecol Oncol2009，113，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员